Agios Recognizes 14th Annual Rare Disease Day and Raises Awareness of Unmet Needs in Rare Hemolytic AnemiasGlobeNewsWire • 02/26/21
Agios Pharmaceuticals, Inc. (AGIO) CEO Dr. Jackie Fouse on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/25/21
Agios Pharmaceuticals (AGIO) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseZacks Investment Research • 02/18/21
Agios to Webcast Conference Call of Fourth Quarter and Year End 2020 Financial Results on February 25, 2021GlobeNewsWire • 02/11/21
Agios Announces Phase 3 ACTIVATE-T Trial of Mitapivat Achieved Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Regularly TransfusedGlobeNewsWire • 01/26/21
Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant CholangiocarcinomaGlobeNewsWire • 01/17/21
Agios Highlights 2021 Milestones to Accelerate and Expand Its Genetically Defined Disease Portfolio and Drive Near- and Long-Term Value CreationGlobeNewsWire • 01/11/21
Agios to Present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021GlobeNewsWire • 01/05/21
Agios to Focus on Developing and Commercializing Innovative Treatments for Genetically Defined Diseases and Sell Its Oncology Business to Servier for Up to $2 Billion Plus RoyaltiesGlobeNewsWire • 12/21/20
Agios Announces Updated Data from Phase 1 Study of Mitapivat, First-in-Class PKR Activator, in Sickle Cell DiseaseGlobeNewsWire • 12/07/20
Agios Pharmaceuticals (AGIO) Up 6.2% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 12/05/20
Agios Launches Anemia ID, a No-Cost Genetic Testing Program for Hereditary AnemiasGlobeNewsWire • 11/30/20